Susan Little

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10419731/publications.pdf

Version: 2024-02-01

279701 377752 3,960 34 23 34 h-index citations g-index papers 34 34 34 5763 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Medicine, 2002, 8, 379-385.	15.2	1,432
2	Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection. PLoS Biology, 2004, 2, e20.	2.6	399
3	Diagnosis of Primary HIV-1 Infection. Annals of Internal Medicine, 2001, 134, 25.	2.0	183
4	Human Immunodeficiency Virus Type 1-Specific CD8 ⁺ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4 ⁺ T Cells. Journal of Virology, 2009, 83, 7641-7648.	1.5	173
5	A Multicenter Observational Study of the Potential Benefits of Initiating Combination Antiretroviral Therapy during Acute HIV Infection. Journal of Infectious Diseases, 2006, 194, 725-733.	1.9	163
6	Sex, Race, and Geographic Region Influence Clinical Outcomes Following Primary HIV-1 Infection. Journal of Infectious Diseases, 2011, 203, 442-451.	1.9	149
7	Dynamics of T Cell Responses in HIV Infection. Journal of Immunology, 2002, 168, 3660-3666.	0.4	137
8	Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. Aids, 2014, 28, 2439-2449.	1.0	133
9	CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV- $1\hat{a}$ e"infected individuals. Nature Medicine, 2008, 14, 413-420.	15.2	118
10	Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers. Journal of Virology, 2010, 84, 7581-7591.	1.5	118
11	Recognition of a Defined Region within p24 Gag by CD8 + T Cells during Primary Human Immunodeficiency Virus Type 1 Infection in Individuals Expressing Protective HLA Class I Alleles. Journal of Virology, 2007, 81, 7725-7731.	1.5	116
12	HIV-specific Cytotoxic T Cells from Long-Term Survivors Select a Unique T Cell Receptor. Journal of Experimental Medicine, 2004, 200, 1547-1557.	4.2	103
13	The Setpoint Study (ACTG A5217): Effect of Immediate Versus Deferred Antiretroviral Therapy on Virologic Set Point in Recently HIV-1–Infected Individuals. Journal of Infectious Diseases, 2012, 205, 87-96.	1.9	92
14	The Effect of Highly Active Antiretroviral Therapy on Binding and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 2000, 182, 945-949.	1.9	79
15	Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. Journal of NeuroVirology, 2013, 19, 65-74.	1.0	72
16	Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. Aids, 2009, 23, 1987-1995.	1.0	67
17	Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection. PLoS ONE, 2010, 5, e10555.	1.1	64
18	Polyclonal Proliferation and Apoptosis of CCR5+T Lymphocytes during Primary Human Immunodeficiency Virus Type 1 Infection: Regulation by Interleukin (IL) \hat{a} \(\epsilon\)2, IL \hat{a} \(\epsilon\)3, and Bcl \hat{a} \(\epsilon\)2. Journal of Infectious Diseases, 2003, 187, 1735-1747.	1.9	63

#	Article	IF	CITATIONS
19	Real-world impact of neurocognitive deficits in acute and early HIV infection. Journal of NeuroVirology, 2013, 19, 565-573.	1.0	43
20	Neurocognitive functioning in acute or early HIV infection. Journal of NeuroVirology, 2011, 17, 50-57.	1.0	40
21	The Virologic and Immunologic Effects of Cyclosporine as an Adjunct to Antiretroviral Therapy in Patients Treated during Acute and Early HIV†Infection. Journal of Infectious Diseases, 2010, 201, 1298-1302.	1.9	33
22	Impaired Nef Function Is Associated with Early Control of HIV-1 Viremia. Journal of Virology, 2014, 88, 10200-10213.	1.5	33
23	Emergence of Individual HIV-Specific CD8 T Cell Responses during Primary HIV-1 Infection Can Determine Long-Term Disease Outcome. Journal of Virology, 2014, 88, 12793-12801.	1.5	30
24	Ethical issues in HIV phylogenetics and molecular epidemiology. Current Opinion in HIV and AIDS, 2019, 14, 221-226.	1.5	18
25	Perceptions of Molecular Epidemiology Studies of Hiv among Stakeholders. Journal of Public Health Research, 2017, 6, jphr.2017.992.	0.5	16
26	"My Death Will Not [Be] in Vain†Testimonials from Last Gift Rapid Research Autopsy Study Participants Living with HIV at the End of Life. AIDS Research and Human Retroviruses, 2020, 36, 1071-1082.	0.5	16
27	Perceptions of Next-of-Kin/Loved Ones About Last Gift Rapid Research Autopsy Study Enrolling People with HIV/AIDS at the End of Life: A Qualitative Interview Study. AIDS Research and Human Retroviruses, 2020, 36, 1033-1046.	0.5	14
28	Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection. Aids, 2014, 28, 841-849.	1.0	11
29	Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 137-141.	0.9	11
30	Associations Between Phylogenetic Clustering and HLA Profile Among HIV-Infected Individuals in San Diego, California. Journal of Infectious Diseases, 2012, 205, 1529-1533.	1.9	10
31	Attitudes and perceptions of next-of-kin/loved ones toward end-of-life HIV cure-related research: A qualitative focus group study in Southern California. PLoS ONE, 2021, 16, e0250882.	1.1	9
32	"[It] is now my responsibility to fulfill that wish:―Clinical and rapid autopsy staff members' experiences and perceptions of HIV reservoir research at the end of life. PLoS ONE, 2020, 15, e0242420.	1.1	6
33	Ethical and practical considerations for interventional HIV cure-related research at the end-of-life: A qualitative study with key stakeholders in the United States. PLoS ONE, 2021, 16, e0254148.	1.1	5
34	Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the United States. BMC Medical Ethics, 2022, 23, 2.	1.0	4